Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer

By Kanai Masashi   Matsumoto Shigemi   Nishimura Takahumi   Shimada Yutaka   Watanabe Go   Kitano Toshiyuki   Misawa Akiko   Ishiguro Hiroshi   Yoshikawa Kiyotsugu   Yanagihara Kazuhiro   Teramukai Satoshi   Mitsumori Michihide   Chiba Tsutomu   Sakai Yoshiharu   Fukushima Masanori  

International Journal of Clinical Oncology, Vol. 12, Iss. 3, 2007-06 ,pp. : 224-227

Springer Publishing Company

Access to resources Recommend Favorite

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

By Boeck Stefan   Heinemann Volker  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 41-50

Future Medicine

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite

Cytokineinduced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature

By              

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1427-1429

Spandidos Publications

Access to resources Recommend Favorite

Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex ( R)) in advanced colorectal cancer

By Farrugia D.C.   Norman A.R.   Cunningham D.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 987-991

Elsevier

Access to resources Recommend Favorite